The coadministration of basal insulin with oral glucose-lowering medications or GLP-1RAs poses a lower risk of hypoglycemia than basal-bolus therapy while retaining the efficiency of the latter in managing blood glucose levels17,18. The gene discussed is INS; the disease is Hypoglycemia.